Free Trial

Zacks Research Has Optimistic View of TriMas FY2024 Earnings

TriMas logo with Industrial Products background

TriMas Co. (NASDAQ:TRS - Free Report) - Equities researchers at Zacks Research increased their FY2024 earnings per share (EPS) estimates for shares of TriMas in a note issued to investors on Monday, January 27th. Zacks Research analyst M. Das now anticipates that the industrial products company will earn $1.71 per share for the year, up from their previous estimate of $1.70. The consensus estimate for TriMas' current full-year earnings is $1.69 per share. Zacks Research also issued estimates for TriMas' Q2 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.48 EPS, FY2025 earnings at $2.04 EPS, Q1 2026 earnings at $0.50 EPS, Q2 2026 earnings at $0.53 EPS and Q3 2026 earnings at $0.56 EPS.

TriMas (NASDAQ:TRS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The industrial products company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.14). TriMas had a net margin of 2.93% and a return on equity of 9.21%. The business had revenue of $229.36 million during the quarter, compared to the consensus estimate of $239.33 million. During the same quarter in the previous year, the firm posted $0.57 EPS. The company's revenue for the quarter was down 2.5% compared to the same quarter last year.

Several other research firms have also recently issued reports on TRS. BWS Financial reiterated a "buy" rating and issued a $40.00 price objective on shares of TriMas in a research report on Thursday, January 23rd. StockNews.com upgraded shares of TriMas from a "sell" rating to a "hold" rating in a research report on Wednesday, November 13th.

Read Our Latest Report on TRS

TriMas Price Performance

Shares of TriMas stock traded up $0.03 during midday trading on Thursday, reaching $24.52. The company had a trading volume of 164,451 shares, compared to its average volume of 230,986. The company has a current ratio of 2.83, a quick ratio of 1.44 and a debt-to-equity ratio of 0.60. The stock has a fifty day simple moving average of $24.99 and a 200 day simple moving average of $25.44. TriMas has a 1-year low of $22.24 and a 1-year high of $28.51. The company has a market capitalization of $994.82 million, a price-to-earnings ratio of 38.31 and a beta of 0.67.

Hedge Funds Weigh In On TriMas

A number of hedge funds and other institutional investors have recently made changes to their positions in TRS. Intech Investment Management LLC acquired a new position in TriMas in the third quarter valued at about $269,000. Paloma Partners Management Co bought a new position in shares of TriMas during the 3rd quarter valued at about $293,000. XTX Topco Ltd acquired a new position in shares of TriMas in the 3rd quarter valued at approximately $371,000. Algert Global LLC increased its stake in TriMas by 4.2% during the 2nd quarter. Algert Global LLC now owns 15,779 shares of the industrial products company's stock worth $403,000 after purchasing an additional 639 shares in the last quarter. Finally, Inspire Investing LLC raised its holdings in TriMas by 17.4% during the 3rd quarter. Inspire Investing LLC now owns 16,155 shares of the industrial products company's stock worth $412,000 after buying an additional 2,389 shares during the period. 99.42% of the stock is owned by institutional investors.

TriMas Company Profile

(Get Free Report)

TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.

Read More

Earnings History and Estimates for TriMas (NASDAQ:TRS)

Should You Invest $1,000 in TriMas Right Now?

Before you consider TriMas, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriMas wasn't on the list.

While TriMas currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

How To Invest in Crypto as A Complete BEGINNER in 2025
3 AI Bargain Stocks to BUY NOW After the DeepSeek Crash
NVIDIA Stock Under Pressure: DeepSeek and the AI Tech War

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines